Month: September 2013

DEA Philadelphia Edition Tip Line

Please see the latest information from the DEA that can be found in the Links section of the website under Keystone Links.  Information on suspected prescription fraud or prescription drug diversion can be submitted ANONYMOUSLY via text or phone.  See

CE Information for November 24, 2013

Check out the newest CE information for Medication Errors Prevention, Surviving a DEA Audit and Fraud Waste and Abuse Training set for Sunday, November 24, 2013 – bottom of the Links section of the website.

Beware of Health Insurance Marketplace Scams – click on box below

House Compounding Legislation Introduced

Bipartisan legislation that would preserve state board of pharmacy oversight of the vast majority of independent community pharmacies that compound medications was introduced in the House last week. H.R. 3089 is sponsored by Reps. Morgan Griffith (R-Va.), Diana DeGette (D-Colo.),

New Keysteone vendor – iMedicare

This is a program developed to help YOU help your patient questions about their Medicare options – be it Advantage programs, Supplement programs or Part D Rx Plans. You can sit down with your patient and an iPad and easily

License Renewal Requirements

Attention Pharmacists! Don’t forget that for your next license renewal, you will need to show that you have 2 hours of your total continuing education hours on the topic of Patient Safety.  Patient Safety qualifying topics are specifically identified by

Speak Out on Compounding Legislation Before It’s Too Late

Congress returns from its summer recess Sept. 9 and swift action on Senate compounding legislation could come any time after that. NCPA has strong concerns about the compounding sections of S. 959, especially a proposed overly broad expansion of authority

Reports: FDA says carve-out bills undermine trust in biosimilars

By Alaric DeArment NEW YORK — The Food and Drug Administration is concerned about bills in several state legislatures that seek to restrict pharmacists’ ability to dispense biosimilars, according to published reports. quoted an FDA spokeswoman as saying “efforts to